İsmail ÇEPNİ, Kimia ÇEPNİ, Ayşe KOCA, Basri GÜNHAN, Songül Çavdar KARAÇAM, Didem Çolpan ÖKSÜZ, Nuran BEŞE

Hodgkin hastalığı mantle ışınlamasında fetus dozlarının araştırılması

Amaç: Hodgkin hastalığı, meme, servikal kanser, malign melanom ve lösemi hamilelik esnasında sıklıkla karşılaşılan malign hastalıklardır. Hamilelik esnasında radyoterapi gelişen fetusa zarar verebilir.Yöntem: Bu çalışmanın amacı Hodgkin hastalığı mantle ışınlaması sırasında hamile hastanın fetusuna verilen radyasyon dozunu ölçmektir. Fetusun aldığı radyasyon dozu termoluminesans dozimetre kullanılarak fantom ölçümleriyle tahmin edildi. Fantom ölçümleri Anthropomorphic fantom tedavi koşullarında simüle edilerek yapıldı.Bulgular: Thermoluminesan dozimetreler (TLD) tedavi alanı merkezinden 41, 44, 46.5 ve 49.5 cm’e yerleştirildi. İki TLD fantom yüzeyine yerleştirildi. Tüm TLD ler için toplam doz Co-60 için olan tedavide 8.8- 13.8; 4 MV foton için olan tedavide 8.2-12.3 cGy olarak ölçüldü.Sonuç: Bu sonuçlar tedavi koşullarında hamile bir hastanın tedaviye alınmasının oluşabilecek maliniteler için risk olduğunu göstermektedir. Fetal koruma kullanımı fetal ışınlamayı azaltabilir.

The investigation of fetal dose for mantle field irradiation of Hodgkin’s disease

Objectives: Hodgkin’s disease, breast and servical cancer, malignant melanoma, and leukaemia are the most frequenly diagnosed malignant disorders during pregnancy. Radiotherapy during pregnancy might cause harm to the developing fetus.Methods: The aim of this work was to estimate the radiation dose delivered to the fetus in a pregnant patient during the mantle field irradiation for Hodgkin’s disease. Radiation dose to fetus was estimated from phantom measurements using thermoluminescence dosimeters. Phantom measurements were performed by simulating the treatment conditions on an anthropomorphic phantom.Results: Thermoluminescent dosimeters(TLDs) were placed in the phantom 41, 44, 46.5 and 49.5 cm from the centre of the treatment field. Two TLDs were placed on the surface of the phantom. The estimated total dose to the all TLDs ranged from 8.8 to 13.8 for treatment with Co-60, and from 8.2 to 12.3 cGy for 4 MV photons.Conclusion: These results show that it is a risk of developing malinancies to treat a pregnant patient with treatment conditions. The use of supplemental fetal-shielding can reduce the fetal exposure.

PDF

___

1. Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. Lancet Oncol 2005; 6: 328-333.
2. Tewari KS. Cancer in pregnancy. In: DiSaia PJ, Creasman WT, eds. Clinical Gynecologic Oncology. 7th ed. Mosby: Elsevier; 2007: 468-531.
3. Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist 2002; 7: 279- 287.
4. Hall EJ, Giaccia AJ. Effects of radiation on the embryo and fetus. Radiobiology for the radiologist. 6th ed. Philadelphia: Lippincott; 2006; 168-180.
5. Pereg D, Koren G, Lishner M. The treatment of Hodgkin’s and non-Hodgkin’s lymhoma in pregnancy. Haematologica 2007; 92: 1230-1237.
6. Hoppe RT. Hodgkin’s disease. In: Perez CA, Brady LW, Halperin EC, Schmidt-Ullrich RK, eds. Principles and practice of Radiation Oncology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2004: 2043-2063.
7. Diehl V, Brillant C, Engert A, et al. HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin’s lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG). J Clin Oncol (Meeting Abstracts) 2005; 23: 6506.
8. Woo SY, Fuller LM, Cundiff JH, et al. Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin’s disease. Int J Radiat.Oncol Biol Phys. 1992; 23: 407-412.
9. Nuyttens JJ, Prado KL, Jenrette JM, Williams TE. Fetal dose during radiotherapy: clinical implementation and review of the literature. Cancer Radiother 2002; 6: 352-357.
10. Zucali R, Marchesini R, De Palo G. Abdominal dosimetry for supradiaphragmatic irradiation of Hodgkin’s disease in pregnancy: experimental data and clinical consideration. Tumori 1981; 67: 203-208.
11. Nisce LZ, Tome MA, He S, et al. Management of coexisting Hodgkin’s disease and pregnancy. Am J Clin Oncol 1986; 9: 146-151.
12. Mazonakis M, Varveris H, Fasoulaki M, Damilakis J. Radiotherapy of Hodgkin’s disease in early pregnancy: embryo dose measurements. Radiother Oncol 2003; 66: 333-339.
13. Cygler J, Ding GX, Kendal W, Cross P. Fetal dose for a patient undergoing mantle field irradiation for Hodgkin’s disease. Med Dosim 1997; 22: 135-137.
14. International Commission on Radiological Protection. Pregnancy and medical radiation. Ann ICRP 2000; 30: 1-43.
15. International Commission on Radiological Protection. Biological effects after prenatal irradiation(embryo and fetus). Ann ICRP 2003; 33: 205-206.
16. Hammer-Jacobsen E. Therapeutic abortion on account X-ray examination during pregnancy. Dan Med Bull 1959; 6: 113-122.
17. Wagner LK, Lester RG, Saldana LR. Exposure of the pregnant patient to diagnostic radiations. 2nd ed. Madison, Wisconsin: Medical Physics Publishing; 1997.
18. Stovall M, Blackwell CR, Cundiff J, Novack DH, et al. Fetal dose from radiotherapy with photon beams: Report of AAPM Radiation Therapy Committee Task Group no: 36. Med Phys 1995; 22: 63-82.
19. Lishner M, Zemlickis D, Degendorfer P, et al. Maternal and fetal outcome following Hodgkin’s disease in pregnancy. Br J Cancer 1992; 65: 114-117.
20. Sneed PK, Albright NW, War WM, et al. Fetal dose estimates for radiotherapy of brain tumors during pregnancy. Int J Radiat Oncol Biol Phys 1995; 32: 823-830.
21. Antypas C, Sandilos P, Kouvaris J, et al. Fetal dose evaluation during breast cancer radiotherapy. Int J Radiat Oncol Biol Phys 1998; 40: 995-999.
22. Greskovich JF, Macklis RM. Radiation therapy in pregnancy: risk calculation and risk minimization. Seminars in Oncology 2000; 27: 633-645.
23. Ioachim HL. Non-Hodgkin’s lymphoma in pregnancy: three cases and review of the literature. Arch Pathol Lab Med 1985; 109: 803-809.